Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 6/20 | 0.57 |
| ▸ | ACE | P12821 | 3/20 | 0.56 |
| ▸ | CPA1 | P15085 | 3/20 | 0.56 |
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.56 |
| ▸ | GNPAT | O15228 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL233445 | 0.97 | MME (0.60) | MMEACECPA1ACE2 | |
| SCHEMBL1864186 | 0.97 | MME (0.60) | MMEACECPA1ACE2 | |
| SCHEMBL31174325 | 0.97 | MME (0.60) | MMEACECPA1ACE2 | |
| SCHEMBL233444 | 0.97 | MME (0.60) | MMEACECPA1ACE2 | |
| SCHEMBL30417812 | 0.94 | MME (0.59) | MMEACECPA1ACE2 | |
| SCHEMBL30414144 | 0.94 | MME (0.59) | MMEACECPA1ACE2 | |
| SCHEMBL30400950 | 0.92 | MME (0.53) | MMEACECPA1ACE2 | |
| SCHEMBL30388715 | 0.92 | MME (0.56) | MMEACECPA1ACE2GNPAT | |
| SCHEMBL29532187 | 0.92 | MME (0.60) | MMEACECPA1ACE2 | |
| SCHEMBL29877007 | 0.92 | MME (0.55) | MMEACECPA1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240033365-A1 | POLY(2-OXAZOLINE)N-f-MLF DERIVATIVE CONJUGATES THAT INHIBIT FORMYL PEPTIDE RECEPTORS FOR THE TREATMENT OF DISEASE | UNIVERSITY OF SOUTH ALABAMA (US) | 2024-02-01 | — | — | US | claimed |
| US-20240024409-A1 | N-f-MLF DERIVATIVES THAT INHIBIT FORMYL PEPTIDE RECEPTORS FOR THE TREATMENT OF DISEASE | UNIVERSITY OF SOUTH ALABAMA (US) | 2024-01-25 | — | — | US | claimed |
| US-20240033365-A1 | POLY(2-OXAZOLINE)N-f-MLF DERIVATIVE CONJUGATES THAT INHIBIT FORMYL PEPTIDE RECEPTORS FOR THE TREATMENT OF DISEASE | UNIVERSITY OF SOUTH ALABAMA (US) | 2024-02-01 | — | — | US | disclosed |
| US-20240024409-A1 | N-f-MLF DERIVATIVES THAT INHIBIT FORMYL PEPTIDE RECEPTORS FOR THE TREATMENT OF DISEASE | UNIVERSITY OF SOUTH ALABAMA (US) | 2024-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240024409-A1 | N-f-MLF DERIVATIVES THAT INHIBIT FORMYL PEPTIDE RECEPTORS FOR THE TREATMENT OF DISEASE | FPR1, FPR2, FPR3 | MME 49/4885ACE 2554/4885CPA1 677/4885 |
| US-20240033365-A1 | POLY(2-OXAZOLINE)N-f-MLF DERIVATIVE CONJUGATES THAT INHIBIT FORMYL PEPTIDE RECEPTORS FOR THE TREATMENT OF DISEASE | FPR1, FPR2, FPR3 | MME 200/4885ACE 4018/4885CPA1 1548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.